With the appointment of de Ribains, AFB declared that it had strengthened its capacities in the area of business creation and development, a key differentiating characteristic in the French market for seed investments in life sciences.
He has a wide range of expertise, including financing, business creation and management, strategic and business planning and product development in the biotechnology, medical technology and diagnostics sectors.
“We are delighted to welcome Geoffroy on board. He brings a rare combination of experience as an investor in life sciences and as an entrepreneur, ”said co-founder and chairman Alain Huriez.
“His experience in setting up and setting up businesses from university research laboratories will be very useful in helping to execute AFB’s strategy of investing in university spin-offs,” he added.
de Ribains was previously CEO of Step Pharma, a Paris-based biotechnology start-up that he co-founded and brought from the discovery of the target to the preclinical candidate stage, raising 16 million euros (18, 8 million dollars) in equity and more than 2 million euros in non-dilutive financing. He is also co-founder of Biomunex Pharmaceuticals.
He brings 12 years of venture capital investment experience with Andera Partners (formerly E. de Rothschild Investment Partners) and Atlas Venture. He was directly involved in 20 new investments, six mergers and acquisitions and three company exits and served on the boards of eight companies.